Frank Boateng, MD
Nephrology · Newark, OHNPI 1609025527
Payments from drug & device makers
What this record shows
This record is dominated by education: $358 of the $513 with a category attached, or 69.8%. 5 manufacturers reported payments, led by Medical Device Business Services, Inc. at 59.5% of the total. 2025 is the largest year on record at $345, more than ten times the $13 reported in 2020. That places this record below the midpoint for nephrology clinicians in OH, where the typical reported total is $965.
Across 22 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$305
- AstraZeneca$91
- Novartis$64
- Travere Therapeutics, Inc.$33
- Aurinia Pharma U.S., Inc.$20
What the payments were for
- Food & beverage$15530%
- Education$35870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 1 | $305 |
| AstraZeneca | 1 | $91 |
| Novartis | 3 | $64 |
| Travere Therapeutics, Inc. | 16 | $33 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
How this compares
$513 in reported general payments places this provider in the 35th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 114 | $82,381 |
| KerendiaFinerenone | 99 | $66,248 |
| JardianceEmpagliflozin | 70 | $53,495 |
| JanuviaSitagliptin Phosphate | 24 | $15,778 |
| Hydralazine Hcl | 199 | $2,302 |
| Torsemide | 91 | $2,151 |
| Calcium Acetate | 30 | $1,673 |
| Midodrine Hcl | 44 | $1,521 |
| Carvedilol | 276 | $1,469 |
| Amlodipine Besylate | 378 | $1,433 |
| Spironolactone | 201 | $1,147 |
| Valsartan | 35 | $1,074 |
| Furosemide | 350 | $888 |
| Nifedipine ErNifedipine | 40 | $840 |
| Losartan Potassium | 128 | $723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $91 | $82,381114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 450 nephrology providers in Ohio.
Other nephrology in Newark
- Brad RovinColumbus$379K
- Nissreen ElfadawyChardon$327K
- Andrew LazarBeachwood$315K
- Amit GovilCincinnati$298K
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Ibrahim AhmadKettering$232K
- Prabir Roy ChaudhuryCincinnati$205K
- Rupesh RainaAkron$163K
- Sevag DemirjianCleveland$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.